Today: 19 July 2026
Browse Category

NASDAQ:MRNA 30 October 2025 - 6 January 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

U.S. stocks rose on Tuesday, lifting the Dow to a fresh record as chip and healthcare shares led gains. At about 2:30 p.m. ET, the Dow was up 1.02% at 49,476.54, while the S&P 500 gained 0.62% to 6,944.55 and the Nasdaq rose 0.61% to 23,537.96. SanDisk jumped 23% and Moderna climbed 10%; Argent Capital portfolio manager Jed Ellerbroek said he expects “a very strong earnings season for Big Tech” and higher capex, short for capital spending. Reuters
6 January 2026
············
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

December 24, 2025 — Moderna, Inc. is ending 2025 with the kind of chart action that makes both traders and long-term biotech investors sit up straight. After a sharp multi-day run, Moderna stock pulled back hard: shares closed at about $32.29 on Dec. 23, down ~7.48% on the day, and were indicated around $32.11 in pre-market trading on Dec. 24. StockAnalysis
24 December 2025
··
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna, Inc. has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration may tighten vaccine approval standards, then rebounded sharply on Friday after a massive French real‑world study reaffirmed the safety and effectiveness of its COVID‑19 vaccine. Investopedia+2Investopedia+2
6 December 2025
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna Inc. enters Sunday, November 23, 2025, as one of the most controversial and heavily shorted stocks in the S&P 500. The biotech is trading near its 52‑week low after the COVID‑vaccine boom faded, yet it’s rolling out a new three‑year strategy, taking on $1.5 billion in debt, cutting pipeline projects and doubling down on its mRNA platform in respiratory disease and cancer. Reuters+3Financial Times+3Barron's+3
23 November 2025
·
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna, Inc. drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2
11 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

U.S. equities opened in the red Thursday, extending this week’s choppy pattern as investors weighed mixed corporate results against macro headwinds. At the bell, all three major indices slipped, with breadth tilting negative. The tone was cautious amid debate over still‑rich tech multiples and uncertain economic signals. Reuters
6 November 2025
······
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1
6 November 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56tradingview.com, reversing much of September–October’s slide. This followed a STAT News report that Moderna has held buyout or partnership talks with at least one large drugmakertradingview.com. Moderna’s shares had been languishing near all-time lowstradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 pricetradingview.com. Moderna declined to comment on the rumors. A company spokesperson reiterated that Moderna is “confident in our strategy,” highlighting that it has advanced several new products this yeartradingview.com.
30 October 2025
··
1 2 3 4
Go toTop